Pulsar Helium Appoints Cliff Cain as Manager of Commercial and External Affairs and Announces Completion of Jetstream #4 with Increased Bottom-Hole Pressure

(TSX-V:PLSR),(OTC US:PSRHF),(Other OTC:PSRHF),(LSE – AIM:PLSR), THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT […]

Crypto Casino No Deposit Bonus: BitStarz Emerges as the Most Popular No Deposit Bonus Platform Among Players

New York City, Nov. 26, 2025 (GLOBE NEWSWIRE) — Nov. 25, 2025 –BitStarz has surged back into the spotlight in 2025, solidifying its dominance in the rapidly expanding crypto casino no deposit market with a series of headline-worthy updates that are reshaping industry standards. Since launching in 2014, the brand has consistently been a front-runner,

Kultura Brands Announces Direct-To-Consumer Launch of Adios Spirits, Marking A New Phase of National Expansion

JACKSON, WY / ACCESS Newswire / November 26, 2025 / Kultura Brands, Inc. , formerly Labor Smart Inc. (OTCID:LTNC) ("Kultura Brands" or the "Company") today announced the official direct-to-consumer (DTC) launch of Adios Spirits, the Company’s flagship tequila-based ready-to-drink beverage brand. Customers can now purchase Adios Spirits directly at https://adiosspirits.com. This launch represents a significant

Pulsar Helium Appoints Cliff Cain as Manager of Commercial and External Affairs and Announces Completion of Jetstream #4 with Increased Bottom-Hole Pressure

Pulsar Helium Appoints Cliff Cain as Manager of Commercial and External Affairs and Announces Completion of Jetstream #4 with Increased Bottom-Hole Pressure GlobeNewswire November 26, 2025 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM

YEAHKA Accelerates Overseas Business Expansion in Q3, Building One-Stop Customer Loyalty Solutions for Brand Clients Such as PlayMade and Jumbo

YEAHKA LIMITED issued a voluntary announcement.It indicates that in the third quarter of 2025, the company's overseas business continues to maintain rapid growth with the gross payment value (GPV) of overseas business reached approximately RMB 1.3 billion, surpassing the full-year overseas GPV in 2024. Moreover, Yeahka's one-stop payment and value-added services continued to support international

The Rise of Cloud Phones: How GeeLark Is Redefining Social Media Marketing

In the past decade, social media marketing has undergone one transformation after another – from desktop-driven campaigns to mobile-first content, from post scheduling to algorithm-driven engagement strategies. Yet, even as the industry evolves, one critical gap has remained: marketers are still relying on desktop-based tools to manage platforms that were designed for mobile.GeeLark, a next-generation

Curasight’s uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment

— Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT® — Site given green light by European Medicines Agency (EMA) and is now open for patient enrollment – first patient dosing expected Q4 2025 — Both arms of Curasight's theranostic approach investigating better treatment (uTREAT®) and diagnosis (uTRACE®)

Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal

— Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy ofZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD) — Findings support the therapeutic potential ofZYMFENTRA in addressing persistent treatment gaps especially in ileum-dominant CD Celltrion, Inc. today announced that a post-hoc analysis of the LIBERTY-CD study, which

Scroll to Top